Editas Medicine, Inc.EDIT
Editas Medicine, Inc. Income Taxes Disclosure
Income Taxes
The Company had no income tax expense due to operating losses incurred for the years ended December 31, 2025 and 2024. During the years ended December 31, 2025 and 2024, the Company did not make any material payments of U.S federal, state, or local income taxes.
A reconciliation of the income tax expense computed using the federal statutory income tax rate to the Company’s effective income tax rate is as follows:
| Year Ended December 31, 2025 | Year Ended December 31, 2024 | ||||||||||||||||||||||
| Amount | Percent | Amount | Percent | ||||||||||||||||||||
| U.S. federal statutory income tax rate | $ | (33,584) | 21.0 | % | $ | (49,743) | 21.0 | % | |||||||||||||||
State and local income taxes, net of federal income tax effect1 | — | — | % | — | — | % | |||||||||||||||||
| Effects of changes in tax laws or rates enacted in the current period | — | — | % | — | — | % | |||||||||||||||||
| Tax Credits | |||||||||||||||||||||||
| Research and development tax credits | (3,541) | 2.2 | % | (5,072) | 2.1 | % | |||||||||||||||||
| Changes in valuation allowance | 32,515 | (20.3) | % | 53,592 | (22.6) | % | |||||||||||||||||
| Nontaxable or nondeductible items | |||||||||||||||||||||||
| Stock-based compensation | 4,441 | (2.8) | % | 568 | (0.2) | % | |||||||||||||||||
| Other | 178 | (0.1) | % | 688 | (0.3) | % | |||||||||||||||||
| Changes in unrecognized tax benefits | — | — | % | — | — | % | |||||||||||||||||
| Other adjustments | (9) | — | % | (33) | — | % | |||||||||||||||||
| Effective income tax rate | — | — | % | — | — | % | |||||||||||||||||
1 State taxes in New Jersey made up the majority (greater than 50 percent) of the tax effect in this category | |||||||||||||||||||||||
The components of the Company’s deferred tax assets and liabilities consist of the following at December 31, 2025 and 2024 (in thousands):
| Year Ended December 31, | |||||||||||
| 2025 | 2024 | ||||||||||
| Deferred tax assets: | |||||||||||
| Net operating loss carryforwards | $ | 231,981 | $ | 170,770 | |||||||
| Tax credit carryforwards | 35,947 | 31,766 | |||||||||
| Accrued expenses | 3,475 | 6,763 | |||||||||
| Capitalized patent costs | 48,075 | 52,178 | |||||||||
| Capitalized research and development expenses, net Sec. 174 | 64,678 | 84,703 | |||||||||
| Capitalized research and development expenses, net Sec. 59(e) | 11,841 | — | |||||||||
| Lease liabilities | 4,763 | 9,134 | |||||||||
| Deferred revenue | 11,712 | 15,755 | |||||||||
| Depreciation and amortization | 1,169 | 978 | |||||||||
| Stock compensation | 7,377 | 10,431 | |||||||||
| Other | 15,421 | 14,976 | |||||||||
| Total deferred tax assets | 436,439 | 397,454 | |||||||||
| Less valuation allowance | (432,196) | (388,967) | |||||||||
| Net deferred tax assets | 4,243 | 8,487 | |||||||||
| Deferred tax liabilities: | (4,243) | (8,487) | |||||||||
| Right-of-use assets | (4,243) | (8,487) | |||||||||
| Net deferred taxes | $ | — | $ | — | |||||||
For taxable years beginning after December 31, 2021, the Tax Cuts and Jobs Act (the "Tax Act”) eliminated the option to deduct research and development expenditures in the current year and required taxpayers to capitalize such expenses pursuant to the Internal Revenue Code of 1986, as amended (the “IRC”), Section 174. For taxable years beginning after December 31, 2024, the One, Big, Beautiful Bill Act (the “OBBA”) eliminates the requirement to capitalize domestic research and development expenditures effected by the Tax Act, but the requirement to capitalize foreign research and development expenditures was not revised. As a result of these provisions, deferred tax assets related to capitalized research expenses pursuant to IRC Section 174 were $64.7 million for the year ended December 31, 2025. Under IRC Section 59(e) taxpayers may elect to capitalize domestic research and development expenditures and amortize these expenses over a ten-year period. As such, deferred tax assets related to capitalized research expenses pursuant to IRC Section 59(e) were $11.8 million for the year ended December 31, 2025.
The Company has incurred net operating losses (“NOLs”) since inception. The Company did not have any international operations as of December 31, 2025. As such, net loss before taxes for the years ended December 31, 2025 and 2024 of $160.1 million and $237.1 million, respectively, is domestic. At December 31, 2025 and 2024, the Company had federal NOL carryforwards of $851.9 million and $612.8 million, respectively. Of the amount as of December 31, 2025, $777.1 million will carryforward indefinitely, while $74.8 million will begin expiring in 2035 and will continue to expire through 2037. As of December 31, 2025 and 2024, the Company also had state NOL carryforwards of approximately $899.5 million and $710.5 million, respectively, which may be available to offset future income tax liabilities and will begin expiring in 2035 and will continue to expire through 2045.
Under the provisions of the IRC, the NOL and research and development tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service (“IRS”) and state tax authorities. NOL and research and development tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the IRC, respectively, as well as other similar state provisions. The Company conducted an analysis under Section 382 to determine if historical changes in ownership through June 30, 2024 would limit or otherwise restrict its ability to utilize its NOL and research and development tax credit carryforwards. As a result of this analysis, the Company does not believe there are any significant limitations on its ability to utilize these carryforwards. However, future changes in ownership occurring after June 30, 2024 could affect the limitation in future years, and any limitation may result in expiration of a portion of the NOL or research and development tax credit carryforwards before utilization.
The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which is principally comprised of NOL carryforwards, research and development tax credit carryforwards, and capitalized license and patent costs. The Company has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets, and as a result, a valuation allowance of $432.2 million and $389.0 million has been established at December 31, 2025 and 2024, respectively. The increase in the valuation allowance of $43.2 million for the year ended December 31, 2025 was primarily due to current period pre-tax losses incurred and research tax credits generated.
The Company applies ASC 740 related to accounting for uncertainty in income taxes. The Company’s reserves related to income taxes are based on a determination of whether, and how much of, a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit.
The following table summarizes the activity related to the Company’s gross unrecognized tax benefits at the beginning and end of the years ended December 31, 2025 and 2024 (in thousands):
| Gross Unrecognized Tax Benefits | |||||
| Balance as of December 31, 2023 | $ | 13,659 | |||
| Gross increases for tax positions related to current year | 2,020 | ||||
| Gross increases for tax positions related to prior year | — | ||||
| Balance as of December 31, 2024 | $ | 15,679 | |||
| Gross increases for tax positions related to current year | 1,420 | ||||
| Gross increases for tax positions related to prior year | — | ||||
| Balance as of December 31, 2025 | $ | 17,099 | |||
At December 31, 2025 and 2024, the Company had unrecognized tax benefits of $17.1 million and $15.7 million, respectively. The Company will recognize interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2025 and 2024, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company’s statement of operations. The Company does not anticipate a material change to unrecognized tax benefits in the next twelve months.
The Company has not as of yet conducted a study of its research and development tax credit carryforwards. This study may result in an adjustment to the Company’s research and development tax credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company’s research and development tax credits, and if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheets or statements of operations if an adjustment were required.
The Company files income tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state, and local income tax authorities for all tax years in which an NOL carryforward is available. There is a 2023 IRS audit in process.
Free Sentinel
Track for freeWant the next Editas Medicine, Inc. income taxes disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment Editas Medicine, Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 9, 2026 | Showing above |
| 2024 | Mar 5, 2025 | |
| 2023 | Feb 28, 2024 | |
| 2022 | Feb 22, 2023 | |
| 2021 | Feb 24, 2022 | |
| 2020 | Feb 26, 2021 | |
About Income Taxes Disclosures
The income tax disclosure reveals how much a company actually pays in taxes versus what the statutory rate would predict. Analysts focus on the effective tax rate (ETR) reconciliation, which breaks down every item driving the gap between the 21% federal rate and the company's reported ETR — including R&D credits, foreign rate differentials, and state taxes. Deferred tax assets (DTAs) and their valuation allowances signal management's confidence in future profitability: a rising allowance suggests the company doubts it can use accumulated tax benefits. Uncertain tax benefit (UTB) reserves quantify exposure to IRS challenges on aggressive positions.
Key signals to watch: sudden ETR drops without clear operational reasons, large increases in valuation allowances, growing UTB balances, and significant unremitted foreign earnings. Post-TCJA, pay attention to GILTI and BEAT provisions that affect multinational tax structures. Compare the cash taxes paid (from the cash flow statement) against the income tax provision to gauge earnings quality.